Last updated: February 13, 2026
Product Overview
NDC 00078-0424 refers to an immunoglobulin product, specifically Octagam 5% Solution for Infusion. It is used primarily for immune deficiencies, autoimmune disorders, and other immunological conditions. The product competes within the plasma-derived immunoglobulin market, which has shown consistent growth driven by expanded indications and improving manufacturing capacity.
Market Size and Trends
Global Immunoglobulin Market
- Valued at approximately $13 billion in 2022.
- Projected compound annual growth rate (CAGR) of 6% between 2023-2030 (source: MarketsandMarkets).
- Driven by increased diagnosis and treatment of autoimmune and immunodeficiency disorders; aging populations; and expanded approved indications.
Key Drivers and Barriers
- Drivers: Rising prevalence of immunological disorders, heightened demand for high-quality plasma-derived products, improved manufacturing yields, and approval of subcutaneous formulations.
- Barriers: High cost of manufacturing, plasma supply constraints, regulatory hurdles, and competition from newer biologics.
Market Competition
- Major players include Grifols, CSL Behring, Takeda, and Octapharma.
- Products are generally characterized by high costs, often exceeding $20,000 per treatment course for chronic indications.
Product Position and Distinctiveness
- Branding: Octagam is a well-established immunoglobulin, with multiple formulations.
- Pricing Trends: Historically, immunoglobulin prices have increased between 3-5% annually, influenced by manufacturing costs and supply constraints.
- Supply Dynamics: Plasma collection bottlenecks affect availability; recent shifts toward synthetic or recombinant alternatives aim to mitigate this.
Pricing Overview (Based on Recent Data)
| Region |
Typical Price Range (per 10g unit) |
Notes |
| US |
$1,600 - $2,200 |
High due to manufacturing regulations and demand |
| EU |
€1,300 - €1,800 |
Prices vary across countries |
| Japan |
¥200,000 - ¥250,000 |
Consistent with high-cost markets |
Pricing Drivers
- Manufacturing complexity of plasma-derived products.
- Regulatory environment and reimbursement policies.
- Competitive landscape and supply constraints.
Price Projections (2023-2030)
- Near-term (2023-2025): Prices expected to stabilize or slightly increase (~2-3% annually) barring significant supply disruptions.
- Mid-term (2026-2030): Incremental increases of 3-4% driven by inflation, manufacturing costs, and market expansion; potential for price erosion if synthetic alternatives gain market share.
Market Opportunities and Risks
Opportunities
- Growing patient populations with autoimmune and immunodeficiency conditions.
- Expanded indications and off-label use.
- Increased plasma donations in regions like the US and Europe.
Risks
- New biologics or recombinant alternatives reducing reliance on plasma-derived products.
- Stringent regulatory requirements impacting OR manufacturing costs.
- Plasma supply challenges, especially post-pandemic.
Regulatory and Policy Environment
- US FDA extended plasma donation and manufacturing requirements, affecting costs and supply.
- EMA mandates centralized approval pathways favoring certain biosimilars or generics.
- Price controls or reimbursement caps in some European countries may limit upside potential.
Summary
NDC 00078-0424, as an Octagam immunoglobulin, operates within a growing but highly regulated and cost-influenced market. Prices are likely to increase modestly over the next several years, with prices in the US ranging from $1,600 to over $2,200 per 10g unit. Supply dynamics and regulatory changes pose significant risk and opportunity factors. Long-term pricing trends will depend on manufacturing efficiencies, market demand, and alternative therapies' development.
Key Takeaways
- The global immunoglobulin market is projected to grow at around 6% CAGR through 2030.
- Prices are currently high, with US costs around $1,600 to $2,200 per 10g unit, expected to rise marginally.
- Supply constraints and new biotherapeutic options could influence pricing and market share.
- Regulatory policies significantly influence manufacturing costs and pricing dynamics.
- Market opportunities exist in expanding indications and regional plasma donations; risks include biosimilar competition and supply disruptions.
FAQs
1. How does plasma supply impact the market for immunoglobulin drugs?
Plasma supply constraints limit production capacity, which can lead to price increases and shortages. Regions with higher plasma donation rates generally see more stable supply.
2. Are biosimilars likely to affect the price of NDC 00078-0424?
Yes. Biosimilars could reduce prices through increased competition, especially if they are approved for the same indications and demonstrate similar efficacy and safety.
3. What are the regulatory hurdles for expanding indications for immunoglobulin products?
Approval requires demonstrating efficacy and safety through clinical trials, which can be costly and time-consuming. Regulatory bodies may also impose manufacturing and quality control standards.
4. How have recent healthcare policies affected pricing trends?
Reimbursement policies and price controls in various regions affect net prices. Tightened regulations in some European countries have capped reimbursement levels, limiting price growth.
5. What is the outlook for synthetic or recombinant alternatives?
Recombinant therapies are in development and may eventually compete with plasma-derived products, potentially reducing overall market prices if they achieve regulatory approval and cost-effectiveness.
Sources
[1] MarketsandMarkets: Immunoglobulin market forecast 2022-2030.
[2] IQVIA (2022): Global plasma-derived therapeutic market analysis.
[3] FDA and EMA regulatory documentation on plasma-derived products.
